Morgan Stanley Iovance Biotherapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,148,574 shares of IOVA stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,148,574

Previous 2,822,863 23.89%

Holding current value

$17.5 Million

Previous $22.6 Million 10.88%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.28 - $11.9 $4.91 Million - $8.02 Million	-674,289 Reduced 23.89%	2,148,574 $20.2 Million
Q2 2024 Oct 17, 2024	BUY	$7.78 - $14.19 $1.03 Million - $1.87 Million	131,842 Added 4.9%	2,822,863 $22.6 Million
Q2 2024 Aug 14, 2024	BUY	$7.78 - $14.19 $1.03 Million - $1.87 Million	131,842 Added 4.9%	2,822,863 $22.6 Million
Q1 2024 Oct 17, 2024	SELL	$7.59 - $17.47 $1 Million - $2.3 Million	-131,842 Reduced 4.67%	2,691,021 $39.9 Million
Q1 2024 Aug 16, 2024	SELL	$7.59 - $17.47 $7.78 Million - $17.9 Million	-1,024,524 Reduced 27.57%	2,691,021 $39.9 Million
Q1 2024 May 15, 2024	SELL	$7.59 - $17.47 $7.78 Million - $17.9 Million	-1,024,524 Reduced 27.57%	2,691,021 $39.9 Million
Q4 2023 Aug 16, 2024	BUY	$3.3 - $8.89 $2.95 Million - $7.94 Million	892,682 Added 31.62%	3,715,545 $30.2 Million
Q4 2023 Feb 13, 2024	BUY	$3.3 - $8.89 $4.07 Million - $11 Million	1,233,420 Added 49.69%	3,715,545 $30.2 Million
Q3 2023 Nov 15, 2023	SELL	$4.44 - $8.79 $4.51 Million - $8.93 Million	-1,015,483 Reduced 29.03%	2,482,125 $11.3 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $22.5 Million - $38 Million	-4,195,083 Reduced 54.53%	3,497,608 $24.6 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $15.1 Million - $22.4 Million	2,722,822 Added 54.79%	7,692,691 $47 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $22 Million - $39.2 Million	3,921,869 Added 374.22%	4,969,869 $31.8 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $3.83 Million - $5.27 Million	-402,057 Reduced 27.73%	1,048,000 $10 Million
Q2 2022 Oct 27, 2022	BUY	$6.38 - $18.33 $5.69 Million - $16.3 Million	891,307 Added 159.52%	1,450,057 $16 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $5.69 Million - $16.3 Million	891,307 Added 159.52%	1,450,057 $16 Million
Q1 2022 Oct 27, 2022	SELL	$12.38 - $19.1 $11 Million - $17 Million	-891,307 Reduced 61.47%	558,750 $9.3 Million
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $3.78 Million - $5.83 Million	305,175 Added 120.35%	558,750 $9.3 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $1.08 Million - $1.8 Million	-65,284 Reduced 20.47%	253,575 $4.84 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $6.49 Million - $8.49 Million	318,859 New	318,859 $7.86 Million

Others Institutions Holding IOVA

# of Institutions

313

Shares Held

241M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account